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Abstract 
The synthesis and evaluation of a series of N,N-bis-heterocyclic-methylamines 1 as isoazaerianin analogues are 
descriebed. It was demonstrated that the replacement of the 3,4,5-trimethoxyphenyl A-ring present in CA-4, isoCA-4 
and isoazaerianin by a quinoline or a quinazoline ring is possible and often beneficiary for a high level of cytotoxicity. 
We have also showed that a carbazole or an indole nucleus are very effective as B-rings in this series, leading to anti-
cancer drugs 1 having a sub-nanomolar level of cytotoxicity (1a: IC50 = 70 pM against HCT116 cells). 1a also display a 
high level of cytotoxicity against four other human cancer cells and inhibited tubulin assembly at a micromolar level. 
Moreover, at a concentration of 5 nM, 1a arrested the cellular cycle in G2/M phase of the cellular cycle and induced 
apoptosis of HCT116 cells. It was also showed that after few hours 1a at a concentration of 10 nM totally disrupted 
endothelial network formation on Matrigel. 
 
Keywords: Cancer, quinoline, quinazoline, carbazole, indole, isoCA-4, cytotoxicity, tubulin. 
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1. Introduction 
In 1989, G. Pettit and co-workers isolated from the bark of an African willow tree, Combretum caffrum, a natural Z-
stilbene, Combretastatin A-4 (CA-4, Figure 1), [1]. This natural compound showed remarkable anti-cancer activities 
displaying a nanomolar level of cytotoxicity against a large panel of human cancer cells including multidrug resistant 
(MDR) cells. [2] CA-4 was found to inhibit the polymerization of tubulin [3] by binding to the colchicine site at a 
micromolar level. It was then showed that its water-soluble prodrug CA-4P (fosbretabulin) reduced blood flow in many 
types of solid tumors [4,5] and particurarly in highly vascular tumors.[6] 
Figure 1. Structures of CA-4, synthetic analogues and target N,N-bis-heterocyclic methylamine targets 
  
CA4-P exerts selectively its antitumor effect by targeting the immature vascularization of tumor thus depriving solid 
tumors of oxygen and essential nutrients leading rapidly to tumor necrosis. In 2016, CA-4P has received the status of 
orphan drug in Europe and USA for the treatment of ovarian cancer, neuroendocrine tumors, certain thyroid cancers and 
more recently for multiform glioma.[7] Despite its proven effectiveness, the main problem associated with CA-4P and 
its parent molecule CA-4 is the ready isomerization of the stilbene Z-double bond into the less active E-form during 
storage, administration and metabolism.[8,9] In an ongoing project aimed to develop stable CA-4 analogues [10], we 
have resolved in 2009 this instability problem by the fortuitous discovery of isoCA-4, a non-natural isomer of CA-
4.[11, 12] We have showed that isoCA-4 displayed exactly the same anti-cancer activities as CA-4 with nanomolar IC50 
cytotoxicity values against a panel of cancer cells and inhibited the tubulin assembly at a micromolar level.[12] 
Moreover, this easy to synthesize and stable 1,1-diarylethylene derivative [13, 14, 15] disrupted newly formed vascular 
tubes in vitro after only 3 h of treatment when it was added at a concentration of 10 nM, to human umbilical vein 
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endothelial cells (HUVECs) thus demonstrating an anti-vascular effect associated to an improved in vivo efficacy.[16] 
In view of the establishment of structure-activity relationships (SARs) we have reported that it was allowed to reduce 
the ethylene double bond (isoerianin derivatives)[17] and to replace the 1,1-ethylene double bond of such drugs by a N-
Me function (isoazaerianin derivatives)[18] with no loss of anti-cancer efficiency. Later, by structural modifications on 
the A-ring of isoCA-4, we have synthesized a series of highly potent cytotoxic isocombretaquinazolines (isoCoQs) [19] 
and isocombretaQuinolines (isoCoQuines) [20] demonstrating for the first time, that the 3,4,5-trimethoxyphenyl A-ring 
present in CA-4 and isoCA-4 can be replaced in these structures by various nitrogen-containing heterocyclic systems. 
Same A-ring replacements (quinazoline or quinaldine vs 3,4,5-trimethoxyphenyl ring) are authorized in the 
isoazaerianin series as it was shown with the discovery of Azixa (verubulin) [21] and 4-anilinoquinolines. [22] A 
similar replacement in A-ring (quinazoline vs 3,4,5-trimethoxyphenyl) was achieved recently by the Mueller group 
which also replaced the classical B-ring of CA-4 by an indole nucleus providing N-methylindol-5yl-quinazolines as 
anti-mitotic agents which displayed a nanomolar level of cytotoxicity against nine cancer cell lines.[23] In the 
continuation to our work in the azaisoerianin series and encouraged by the interesting results obtained with quinolines 
and quinazolines, we now wish to report the synthesis and biological evaluation of a novel series of isoerianin 
derivatives in which both A- and B-phenyl-rings were replaced by various heterocyclic systems to provide an original 
potent series of N,N-bis-heterocyclic methylamines (Figure 1). Preliminary in vitro cytotoxicity and inhibition of 
tubulin polymerization (ITP) results of these novel heterocyclic structures will be presented and discussed. The effects 
of the more cytotoxic molecule 1a on the cellular cycle and as apoptosis inductor in human colon carcinoma (HCT116) 
will be showed. Promising in vitro antivascular properties of 1a will be mentioned as 1a disrupted rapidly in vitro 
vessel-like structures formed by human umbilical vein endothelial cells (HUVEC) on Matrigel. By analogy to 1,1-
diarylathylene derivatives, 1,1-bis-heteroaryl-ethylene derivatives which could be possible potent anti-tubulin drugs are 
currently studied in our Lab and will be presented later. 
Scheme 1. Synthesis of compounds 1a-p 
 
aReagents and conditions: (a) HCl, dioxane, 100 °C, 12 h. (b) CH3I (1.2 equiv), Cs2CO3 (1.2 equiv), DMF, rt (c) CF3SO3H, CF3CO2H, 85 °C, 4 h. (d) 
CH3COCl, AlCl3, CH2Cl2, reflux, 1h 30. (e) NaBH4, CH2Cl2 /MeOH, rt 2 h. (f) HNO3, CH2Cl2, rt, 1h 30. (g) Fe/HCl, reflux. (h) BBr3, CH2Cl2, rt, 2 h 
(i) CH3I (2.4 equiv), Cs2CO3 (2.4 equiv), DMF, rt (j) Pd2dba3, BINAP, Cs2CO3, dioxane, 130 °C, MWI, 1h 30 then POCl3, NEt3, 90 °C, 4 h. 
 4 
2. Results and discussion 
2.1. Chemistry 
Firstly, we have prepared a series of N,N-bis-heterocycles methylamines 1-3 having as B-ring a variously substituted 
carbazole backbone as B-ring and as A-ring, a series of quinolines, quinazolines and pyridines in view to establish 
structure-activity relationships (SARs). The synthesis of the targets N,N-quinolinocarbazole methylamines 1a-p bearing 
a substituted quinoline-A-ring and a substituted carbazole B-ring is outlined in Scheme 1. The target compounds 1a-h 
were easily prepared in two steps from the SNAr reaction between 2-substituted-4-chloroquinolines with various 5-
aminocarbazoles followed by N-methylation of the resulting secondary amine.24 For solubility considerations, a polar 
ethanol function was introduced on the 3-position of carbazole 1a by a Friedel-Craft acylation followed by NaBH4 
reduction to give 1j (80%). A NH2-function was also introduced of the 3-position of carbazole 1a after a regioselective 
nitration followed by NO2-reduction to furnish 1l. Similarly, by chemical transformation on the quinoline-ring of 1f 
(demethylation) and 1g (reduction), we prepared 1m and 1n with a similar 87% yield. We have also synthesized the 
ammonium salt 1o for solubility considerations from the SNAr reaction between 4-bromoquinoline and 9-methyl-9H-
carbazol-3-amine. The resulting secondary amine (which was not isolated) was rapidly alkylated in the presence of an 
excess of CH3I and Cs2CO3 to give the water-soluble salt 1o. Finally, the 2-chloroquinoline derivative 1p was prepared 
in three steps from the Pd-coupling reaction between 9-methyl-9H-carbazol-3-amine and 2-hydroxyquinolin-4-yl triflate 
followed C2-chlorination and N-methylation reactions. Then, we have replaced the quinoline nucleus in compounds 1a 
and 1p by a quinazoline heterocycle as A-ring to provide the expected bis heterocycles N-methylamines 2a,b in 
accordance to our previous results in the isoCoQ series [19] and also by a pyridine ring (3) (Scheme 2). The synthesis of 
the desired targets 2a,b and 3 was achieved according to a similar strategy used for quinolines 1a-p (Scheme 2). 
Scheme 2. Synthesis of target compounds 2a,b and 3a 
 
aReagents and conditions: (a) HCl, dioxane, 100 °C, 12 h. (b) CH3I (2.2 equiv), Cs2CO3 (2.2 equiv), DMF, rt 
We next replaced the carbazole B-ring present in compounds 1-3 by a variety of other heterocycles and notably by an 
indole nucleus to prepare a second series of bis-heterocyclic derivatives 4a,b as it has been previously demonstrated 
that indoles analogues compounds were very potent as antiproliferative and anti-mitotic derivatives [23] (Scheme 3). By 
using a SNAr reaction followed by N-methylation process, we were not able to prepare the desired N,N-bis-
quinolineindole methylamines 4a,b. This problem was solved using the required 4-chloroquinolines and Pd2dba3 as a 
catalyst, Xphos as a ligand in the presence of NaOtBu as a base in hot toluene (100 °C for 12 h) and the targets 4a,b 
were obtained with variable yields (14% and 62%, respectively). From the easy available 4-chloroquinaldine, we have 
also directly connected an indole nucleus on the C-4 of the quinoline ring providing the expected constraint derivative 5 
(95%). Next we have synthesized various substrates having a 2-methylquinoline (quinaldine) as A-ring and various 
modifications on the B-ring by introduction of a 2,3-chloro-methoxy pyridine 6 (29% for the two steps) which was next 
converted by Pd-chemistry into 7 and 8. Compound 9 was prepared in two steps (62%) from the condensation of 4-
chloroquinaldine with 2,3-dihydrobenzo[b][1,4]dioxin-6-amine followed by N-methylation. A quinazoline A-ring was 
also introduced in place of the 4-methylquinoline nucleus in compound 4a to furnish, after N-methylation the desired 
target 10 bearing both a quinazoline and an indole nucleus as A- and B-rings respectively. Finally, we have synthesized 
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starting from 4-chloroquinaldine, derivative 11 which could be regarded as a chimera between isoCoQuines and 
isoazaerianin (12% for the two steps) having two quinaldine rings separated by our best ethylene- and N-methylamine 
linkers. For comparisons with carbazole 1a, we have prepared the dibenzofuran 12 according to the sequence: SNAr 
reaction between 4-chloroquinaldine and 2-aminodibenzo[b,d]furan followed by N-methylation process. 
Scheme 3. Synthesis of target compounds 4-12 
 
aReagents and conditions: (a) Pd2dba3, Xphos, NaOtBu, toluene, 100 °C, 24 h (b) Pd(OAc)2, Xantphos, Cs2CO3, toluene, 100 °C, 12 h (c) HCl, 
dioxane, 100 °C, 12 h. (d) CH3I (1.2 equiv), Cs2CO3 (1.2 equiv), DMF, rt (e) Pd2dba3, Xphos, KOH, dioxane/H2O, 90 °C, 12 h (f) Pd2dba3, 
tBuBretphos, NaOtBu, NH3, dioxane, 100 °C, 12 h. (g) KOtBu, THF/H2O, rt, 24 h. 
2.2. Biological results 
2.2.1 Cytotoxicity assays 
In vitro cytotoxicity of the newly synthesized drugs 1-12 was investigated against HCT116, a human colon carcinoma 
cell line. A colorimetric-based assay was used to determine the drug concentration required to inhibit cell growth by 
50% (IC50) after incubation in the culture medium for 72 h. IsoCA-4 was included as the reference for comparisons.[25] 
To investigate whether these derivatives were exerting their activity by interactions with microtubules, all novel 
compounds 1-12 were also evaluated for their potential to inhibit -tubulin assembly. The cytotoxicity and the anti-
tubulin results of compounds 1-12 are presented in Table 1. 
The results depicted in Table 1 showed that nine compounds (1b, 12 nM; 1f, 21 nM; 1p, 16 nM; 2a, 2 nM; 2b, 1 nM; 
4a, 2 nM; 4b, 3 nM; 8, 1 nM; 9, 20 nM) displayed an interesting nanomolar level of cytotoxicity against HCT116 cells. 
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Table 1 Cytotoxicity against HCT116 cellsa and ITP of compounds 1-12 
Compound 1a 1b 1c 1d 1e 1f 1g 
Cytotoxicity 
IC50b [nM] 
0.070 ± 0.001 12 ± 0.8 847 ± 60 943 ± 7.  Nad 21.6 ± 0.71 623 ± 3.87 
 
      
 
ITP IC50c [M] 1.13 ± 0.16 1.40 ± 0.51 Nad Nad Nad 1.48 ± 0.52 Nad 
Compound 1h 1i 1j 1k 1l 1m 1n 
Cytotoxicity 
IC50b [nM] 
186.1 ± 6.70 Nad 219.2 ± 15.1 Nad 2.88 ± 1.54 50.6 ± 0.66 24.5 ± 1.92 
 
  
 
   
 
ITP IC50c [M] Nad Nad Nad Nad 2.76 ± 0.5 1.24 ± 0.40 5.76 ± 1.47 
Compound   1o 1p 2a 2b 3 4a 4b 
Cytotoxicity 
IC50b [nM] 
891 ± 22 16.7 ± 0.38 2.4 ± 0.2 1.06 ± 0.2 879 ± 36 2.00 ± 0.04 3.28 ± 0.18 
 
       
ITP IC50c [M] Nad 1.16 ± 0.31 3.8± 0.9 3.14 ± 1.04 Nad 1.34 ± 0.45 2.50 ± 0.54 
Compound 5 6 7 8 9 10 11 
Cytotoxicity 
IC50b [nM] 
482 ± 3.7 461.8 ± 183.3 205 ± 18 1.73 ± 0.03 20.7 ± 0.25 0.20 ± 0.01 969 ± 4.76 
 
  
 
   
 
ITP IC50c [M] Nad Nad Nad 0.90 ± 0.19 4.08 ± 1.49 1.19 ± 0.28 Nad 
Compound 12 isoCA-4      
Cytotoxicity 
IC50b [nM] 
843.6 ± 15.5 1.80 ± 0.10      
 
  
     
ITP IC50c [M] Nad 1.0 ± 0.1      
a HCT116 Human colon carcinoma. b IC50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment with 
the tested drug (average of three experiments). c IC50 is the concentration of compound required to inhibit 50% of the rate of microtubule assembly 
(average of three experiments). d Not active 
More interestingly, two compounds exhibited a sub-nanomolar level of cytotoxicity (1a, 70 pM; 10, 0.20 nM). The 
replacement of the methyl group present on the C2 of the most cytotoxic derivative 1a by withdrawing groups resulted 
in a variable loss of cytotoxicity (1b, R = CN, 12 nM; 1c R = CF3, 850 nM; 1p, R = Cl, 16 nM). Similarly, the 
introduction of substituents on both quinoline (1f and 1g) and carbazole (1j-1m) parts of 1a led to less potent cytotoxic 
drugs. As showed in Table 1, the nitrogen atom N1 of the carbazole nucleus present in 1a is preferably substituted by a 
methyl group as the non-substituted derivative 1i was not active and other substitutions (1e, N-Bn; 1h, N-Et) were not 
efficient. We were pleased to observe that the replacement of the carbazole ring in 2b (IC50 = 12 nM) by an indole led 
to highly cytotoxic indole derivative 10 (IC50 = 0.2 nM). Through the examples of heterocycles presented in Table 1, 
however, we believe that it is far from obvious to establish reliable structure-activity relationships (B-ring: indole vs 
carbazole and A-ring: quinolines vs quinazolines) to further improve the level of cytotoxicity of such drugs. 
So, we next investigated the effects of the two more cytotoxic compounds, quino-NMe-carbazole 1a (QnNCz) and 
quinazo-NMe-indole (QzNIn) 10 against HCT116 cells on the proliferation of six other tumor cell lines: human ovarian 
carcinoma  (A2780), cis-platin resistant human ovarian carcinoma (A2780R), Human pancreatic carcinoma (MiaPaca2), 
chronic myeloid leukemia cells (K562R), doxorubicin-resistant chronic myeloid leukemia cells (K562R) and breast 
cancer cells (JIM-T1). 
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Table 2. Cytotoxicity and IC50 valuesa (nM) of 1a and 10 against A2780, A2780R, MiaPaca, K562, K562R and JIM-T1 
cells 
Compounds A2780 A2780R MiaPaca2 K562 K562R JIM-T1 
1a 0.53 ± 0.04 0.54 ± 0.09 0.47 ± 0.01  0.60 ± 0.08 0.28 ± 0.02 0.36 ± 0.02 
10 0.24 ± 0.05 2.34 ± 0.18 0.62 ± 0.02 0.77 ± 0.10 1.77 ± 0.16 0.52 ± 0.02 
isoCA-4 3.01 ± 0.62 2.66 ± 0.54 5.0 ± 0.4 0.80 ± 0.1 1.1 ± 0.2 3.08 ± 0.25 
a IC50 is the concentration of compound needed to reduce cell growth by 50% following 72 h cell treatment with the tested drug (average of three 
experiments). 
QnNCz 1a displayed a sub-nanomolar level of cytotoxicity against A2780, A2780R, MiaPaca2, K562, K562R and JIM-
T1 cancer cells ranging from 0.28 to 0.60 nM. Similarly, QzNIn 10 which displayed a sub-nanomolar level of 
cytotoxicity against HCT116 cell lines (0.2 nM) also displayed an interesting nano- (A2780R, 2.34 nM; K562R, 1.77 
nM) or sub-nanomolar (A2780, 0.24 nM; MiaPaca2, 0.62 nM; K562, 0.77 nM; JIM-T1, 0.52 nM) level of cytotoxicity. 
These results demonstrated that these two couples of N-bis-heterocycles-methylamines drugs bearing, from one hand, a 
quinaldine and a carbazole scaffold and from the other hand a quinazoline and an indolic backbone are very potent 
antiproliferative compounds which were 10-fold more cytotoxic than isoCA-4. This very promising results encourage 
us to improve these cytotoxic effects through the introduction(s) of suitable substituent(s) on heterocycles in a near 
future. 
2.2.2. Inhibition of tubulin polymerization (ITP) 
All compounds depicted in Table 1 were next evaluated for their inhibitory activities of tubulin polymerization and 
isoCA-4 was employed as negative control. As we can see, all more cytotoxic drugs against HCT116 cells having a 
nanomolar or a picomolar cytotoxicity level inhibited tubulin assembly at a micromolar level. Particularly, quinaldine-
carbazole derivative 1a and quinazoline indole substrate 10 having sub-nanomolar cytotoxicity levels, strongly tubulin 
assembly with IC50 values of 1 M which are similar to that of the positive control isoCA-4. In contrast, all new 
derivatives which were found to be significantly less cytotoxic against HCT116 cells (having a IC50 value superior to 
200 nM) were found inactive against tubulin at the concentration tested (10 M). The concentrations required to inhibit 
tubulin polymerization using 1a (IC50: 1 μM) is much higher than those required for cytotoxicity (IC50 in the nanomolar 
and sub-nanomolar range). Similar observations have been previously noticed in many other classes of antimitotic 
agents, including epithilones,[26] paclitaxel,[27] and isoCA-4 analogues prepared in our group. The basis for this 
difference has been attributed to intracellular retention of these compounds, leading to higher intracellular 
concentrations.[27] Moreover, the tubulin polymerization test consists in a rapid turbidimetric assay that examines 
instantaneous effects on polymerization. The difference between long-term continuous treatment in the cell-based assay 
(72 h) and instant measurements explain such concentration differences.[28] Furthermore, the effects of 1a on cell cycle 
progression (see section 2.2.3) correlated well with its strong antiproliferative activity and inhibition of tubulin 
polymerization. We observed accumulation of G2/M and apoptotic cells, effects expected for compounds that interact 
with tubulin. Such observations would strongly suggest that -tubulin is (one of) the target(s) of 1a and its structural 
analogues. Moreover, we recently determined the X-ray crystal structure of 1a derivative (having a carbazole and a 
quinaldine moieties) bound to tubulin showing that tubulin was a relevant target for these compounds.[29]  
QnNCz 1a the most cytotoxic derivative which displayed against the five tested cancer cell lines a very high and 
homogeneous cytotoxicity level (0.07 nM <IC50 < 0.54 nM) was next evaluated in dose-response experiments on 
HCT116 cell cycle distribution. HCT116 cells were treating for 24 h with increasing nanomolar concentrations (1, 5 and 
10 nM) and DMSO was used as control. As seen in Figure 2, when QnNCz 1a was used at a concentration of 5 nM, the 
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great majority of HCT116 cells were arrested in the G2/M phase of the cellular cycle as we previously observed with all 
isoCA-4 derivatives. [10a] 
2.2.3 Cell cycle analysis 
Figure 2. Determination by flow cytometry analysis of the effects of 1a on cell cycle distribution in HCT116 cells. 
DNA content was assessed via propidium iodide staining 
 
 Number of cells (%) 
 GO/G1 S G2/M 
DMSO 37 40 23 
1a 10 nM 0 18 82 
1a 5 nM 8 12 80 
1a 1 nM 35 40 25 
 
QnNCz 1a the most cytotoxic derivative which displayed against the five tested cancer cell lines a very high and 
homogeneous cytotoxicity level (0.07 nM <IC50 < 0.54 nM) was next evaluated in dose-response experiments on 
HCT116 cell cycle distribution. HCT116 cells were treating for 24 h with increasing nanomolar concentrations (1, 5 and 
10 nM) and DMSO was used as control. As seen in Figure 2, when QnNCz 1a was used at a concentration of 5 nM, the 
great majority of HCT116 cells were arrested in the G2/M phase of the cellular cycle as we previously observed with 
isoCA-4 at the same concentration. [12] 
2.2.4 Apoptosis 
Cell-cycle arrest in the G2/M phase is frequently followed by DNA fragmentation and by other morphological features 
of apoptosis. The abitity of QnNCz 1a to induce apoptosis was next evaluated by a specific apoptosis assay using 
cleavage of pro-caspases to active caspases. HCT116 cells were incubated with 0.5, 1, 5 and 10 nM of 1a for 24 h and 
caspases -3 and -7 activity was evaluated using the standard caspases assay and DMSO was used as reference. The 
results presented in Figure 3 show a significant dose-dependent increase in proteolytic activity of caspases in HCT116 
cells treated with QnNCz 1a meaning that QnNCz 1a induced apoptosis at a low concentration of 5 nM. 
Figure 3. Apoptotic effects of 1a in HCT116 cells 
Rhodamine 111 Relative Fluorescence 
          (Intensity (% of control) 
 
                                            Concentration of 1a 
2.2.5 Effect on Human Umbilical Vein Endothelial Cells Organization on Matrigel 
The ability of endothelial cells to form tubular structures when plated on a Matrigel matrix allows the observation of 
three-dimensional organization of endothelial cells and offers an in vitro model of antivascular activities. When seeded 
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on Matrigel, flattened endothelial cells aggregate to form a reticular vascular network of capillary-like vessels (Figure 
4). 
Figure 4. Inhibitory activity of QnNCz 1a on in vitro tubular structures. QnNCz 1a (10 nM) was added to the vascular 
tubes formed during 24 h by HUVEC on Matrigel. Images were taken 2, 3 and 5 h after addition of QnNCz 1a and 
DMSO was used as reference 
 t = 0 t = 2 h t = 3 h t = 5 h 
 
DMSO 
0.1 % 
    
QnNCz 
1a 
(10 nM) 
    
After 2, 3 and 5 h, the addition of QnNCz 1a on tubular structures at a concentration of 10 nM, rapidly disrupted the 
integrity of the network in a similar fashion as observed with isoCA-4.[12] This result strongly suggests that QnNCz 1a 
might be a possible lead compound for an antivascular therapy. It is also interesting to note that after 2, 3 and 5 h, 
QnNCz 1a did not display any cytotoxicity against HUVECs (data not showed) whereas after 72 h of treatment, QnNCz 
1a was highly cytotoxic against HUVECs displaying an antiproliferative activity with a GI50 value of 3.23 ± 0.28 nM. 
This observation indicated the in vitro antivascular effect observed with 1a on HUVECs after short times (2, 3, 5 h) is 
not correlated with its cytotoxic properties only observed at the same nanomolar concentration but after a prolongated 
time. 
3. Conclusion 
In this work, we have designed and synthesized a series of isoerianin derivatives having different heterocycles as A- and 
a B-rings. We found that best combinations associate in their structures (i) a quinaldine and a carbazole nuclei 
connected to the NMe group (e.g. 1a) and also (ii) a quinazoline and an indole linked to the NMe spacer (e.g. 10). The 
more interesting drug in these novel series is undeniably QnNCz 1a which displayed a very promising picomolar level 
of cytotoxicity against five cancer cell lines and inhibited tubulin polymerization with a micromolar IC50 values. After 
treatment with QnNCz 1a, HCT116 cells were arrested in the G2/M phase at a concentration of 5 nM as it was observed 
with other isoerianin derivatives. [17] Moreover, preliminary in vitro results reveal that, at nanomolar concentrations, 
QnNCz 1a was a strong apoptosis inducer and also a very potent vascular disrupting agent which disrupted vessels-like 
structures on Matrigel. Other variations in heterocyclic systems are currently under investigation in our lab and will be 
published later. 
4. Experimental 
4.1. General considerations 
The compounds were all identified by usual physical methods, i.e. 1H NMR, 13C NMR, 19F NMR, IR, HRMS. 1H, 13C 
and 19F NMR spectra were measured in CDCl3 with a Bruker AMX 200 (1H, 13C and 19F) or with a Bruker Avance 300 
(1H and 13C). 1H chemical shifts are reported in ppm from an internal standard TMS or of residual chloroform (7.27 
ppm). The following abbreviations are used: m (multiplet), s (singlet), d (doublet), brs (broad singlet), t (triplet), 13C 
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chemical shifts are reported in ppm from the central peak of CDCl3 (77.14). IR spectra were measured on a Bruker 
Vector 22 spectrophotometer (neat, cm-1). Mass spectra were obtained with a LCT Micromass spectrometer. Analytical 
TLC was performed on Merck pre-coated silica gel 60F plates. Merck silica gel 60 (230-400 mesh) was used for 
column chromatography.  
 
4.2. General procedure for the synthesis of compounds 1a-h, 2a-b, 3, 6, 9, 11, 12 
In a sealed tube were added successively ArCl and aniline derivative in dioxane (2 mL). One drop of HClconc. was added 
and the mixture was stirred at 100 °C for 12 h. EtOAc was added to the cooled mixture which was neutralized with 
NaOHaq. (5N). After extraction, organic layer was dried on Na2SO4, filtered and concentrated. The crude mixture was 
added to a solution of Cs2CO3 (1.2 equiv.) in DMF (5 mL) at 0 °C. CH3I (1.2 equiv.) was added dropwise at 0 °C and 
the mixture was stirred at room temperature for 12 h. The crude mixture was concentrated and purified by silica gel 
column chromatography.  
N,9-Dimethyl-N-(2-methylquinolin-4-yl)-9H-carbazol-3-amine 1a (24%) 
Yellow solid, F = 197.9 - 198.2 °C. 1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 3.2 Hz, 1H), 7.97 (d, J = 3.8 Hz, 1H), 
7.80 (d, J = 2.1 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.49 (t, J = 7.3 Hz, 2H), 7.39 (d, J = 8.2 Hz, 1H), 7.33 – 7.25 (m, 
1H), 7.22 (d, J = 7.1 Hz, 1H), 7.17 (dd, J = 8.7, 2.1 Hz, 1H), 7.05 (t, J = 7.3 Hz, 1H), 6.97 (s, 1H), 3.82 (s, 3H), 3.57 (s, 
3H), 2.77 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.4, 154.4, 149.8, 143.5, 141.7, 138.0, 129.0, 128.7, 126.1, 125.3, 
124.1, 123.6, 122.5, 122.2, 121.8, 120.6, 118.9, 114.8, 110.9, 109.3, 108.7, 44.2, 29.3, 25.8. IR film νmax/ cm-1: 1586, 
1509, 1485, 1470, 1413, 1387, 1357, 1333, 1289, 1243, 1179, 1153, 1122, 1102, 1060. HRMS calcd for C24H22N3 [M + 
H]+ 352.1814, obsd 352.1808. HPLC [H2O+ 0.1% formic acid / ACN – grd 1-100] r. t.: 18.00 min, purity: 100%. 
4-(Methyl(9-methyl-9H-carbazol-3-yl)amino)quinoline-2-carbonitrile 1b (28%) 
Pale yellow solid. F = 232.9 - 233.8 °C. 1H NMR (300 MHz, CDCl3) δ 7.92 (t, J = 8.2 Hz, 2H), 7.75 (d, J = 2.2 Hz, 
1H), 7.51 – 7.38 (m, 3H), 7.34 (d, J = 8.2 Hz, 1H), 7.26 (d, J = 8.2 Hz, 1H), 7.22 – 7.07 (m, 3H), 7.06 – 6.97 (td, J = 
8.2 Hz, J = 2.2 Hz, 1H), 3.79 (s, 3H), 3.52 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 154.7, 149.9, 142.2, 141.7, 138.7, 
134.2, 130.3, 129.8, 126.6, 126.4, 125.7, 123.7, 122.9, 122.7, 122.2, 120.5, 119.2, 118.3, 116.3, 110.6, 109.7, 108.8, 
44.8, 29.3. IR neat νmax/ cm-1: 2962, 2928, 2885, 2361, 2341, 1711, 1648, 1601, 1542, 1484, 1390, 1288, 1220, 1155, 
1060, 972. HRMS calcd for C24H19N4 [M+H]+ 363.1610, obsd 363.1614. HPLC [H2O+ 0.1% formic acid / ACN – grd 
5-100] r. t.: 20.90 min, purity: 100%. 
N,9-Dimethyl-N-(2-(trifluoromethyl)quinolin-4-yl)-9H-carbazol-3-amine 1c (26%) 
Pale yellow solid. F = 190.3 - 192.0 °C. 1H NMR (300 MHz, CDCl3) δ 8.06 (dd, J = 7.8 Hz, J = 2.2 Hz, 1H), 7.94 (d, J 
= 7.8 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.58 – 7.41 (m, 3H), 7.36 (d, J = 8.2 Hz, 1H), 7.33 – 7.23 (m, 2H), 7.24 – 7.10 
(m, 2H), 7.04 (td, J = 7.8 Hz, J = 6.8 Hz, 1H), 3.81 (s, 3H), 3.59 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.5, 149.1, 
148.1 (q, J = 135 Hz), 142.7 (2), 141.6, 138.5, 130.4, 129.5, 126.3, 126.0, 125.6, 123.7, 122.8, 122.3, 122.0 (q, J = 1.1 
kHz), 120.5, 119.1, 116.1, 109.6, 108.8, 104.0, 44.7, 29.2. 19F NMR (188 MHz, CDCl3) δ -68.11. IR neat νmax/ cm-1: 
3052, 2961, 2918, 2851, 1585, 1570, 1494, 1426, 1400, 1171, 1142, 1124, 1104, 938, 733. HRMS calcd for C24H19F3N3 
[M+H]+ 406.1531, obsd 406.1534. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 23.55 min, purity: 100%. 
N,9-Dimethyl-N-(quinolin-4-yl)-9H-carbazol-3-amine 1d (25%) 
Brown solid. F = 222.2 - 228.4 °C. 1H NMR (300 MHz, DMSO) δ 8.84 (d, J = 8.5 Hz, 1H), 8.54 (d, J = 7.3 Hz, 1H), 
8.29 (d, J = 2.8 Hz, 1H), 8.26 – 8.13 (m, 3H), 7.91 (t, J = 8.2 Hz, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.67 (d, J = 8.2 Hz, 
1H), 7.54 (td, J = 5.7 Hz, J = 2.8 Hz, 2H), 7.25 (t, J = 7.3 Hz, 1H), 6.71 (d, J = 7.3 Hz, 1H), 4.17 (s, 3H), 3.96 (s, 3H). 
13C NMR (75 MHz, DMSO) δ 155.5, 147.6, 141.3, 139.7, 138.8, 134.3, 128.1, 127.2, 126.5, 123.9, 123.8, 122.8, 121.6, 
120.7, 119.2, 118.8, 118.0, 117.7, 110.5, 109.6, 99.7, 42.2, 29.3. IR neat νmax/ cm-1: 3439, 3052, 2962, 2850, 1615, 1555, 
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1363, 1144, 1121, 1104, 1058, 746. HRMS calcd for C23H20N3 [M+H]+  338.1657, obsd 338.1662. HPLC [H2O+ 0.1% 
formic acid / ACN – grd 5-100] r. t.: 13.91 min, purity: 96%. 
9-Benzyl-N-methyl-N-(2-methylquinolin-4-yl)-9H-carbazol-3-amine 1e (59%) 
White solid. F = 192.7 - 196.5 °C. 1H NMR (300 MHz, CDCl3) δ 8.67 (d, J = 8.7 Hz, 1H), 8.06 (d, J = 7.7 Hz, 1H), 
7.96 (s, 1H), 7.58 – 7.41 (m, 5H), 7.30 (s, 2H), 7.26 – 7.14 (m, 5H), 7.02 – 6.94 (t, J = 8.4 Hz, 1H), 6.80 (s, 1H), 5.57 
(s, 2H), 3.80 (s, 3H), 3.03 (s, 3H).13C NMR (75 MHz, CDCl3) δ 157.0, 155.3 (2), 141.6, 140.8, 139.1, 136.7, 131.6, 
129.0 (2), 127.9, 127.1, 126.5 (2), 126.1, 125.4, 124.4, 123.1, 123.0, 122.5, 120.9, 120.0, 119.1, 116.9, 110.7, 109.6, 
106.9, 47.0, 45.7, 21.8. IR neat νmax/ cm-1: 3062, 2823, 2360, 2201, 1630, 1595, 1507, 1482, 1380, 906. HRMS calcd for 
C30H26N3 [M+H]+ 428.2127, obsd 428.2115. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 14.33 min, 
purity: 100%. 
N-(8-Methoxy-2-methylquinolin-4-yl)-N,9-dimethyl-9H-carbazol-3-amine 1f (45%) 
Yellow solid. F = 137.6 - 143.3 °C. 1H NMR (300 MHz, CDCl3) 8.02 (d, J = 7.9 Hz, 1H), 7.86 (d, J = 2.0 Hz, 1H), 7.56 
– 7.51 (m, 1H), 7.46 (d, J = 4.0 Hz, 1H), 7.41 (d, J = 4.0 Hz, 1H), 7.30 – 7.22 (m, 2H), 6.98 – 6.86 (m, 4H), 4.09 (s, 
3H), 3.90 (s, 3H), 3.77 (s, 3H), 3.15 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 156.3, 156.0, 152.4, 141.8, 141.5, 138.9, 
136.5, 126.6, 124.8, 123.8, 122.6, 122.3, 121.0, 120.7, 119.4, 117.5, 117.2, 116.0, 109.8, 109.3, 108.9, 108.9, 56.2, 
45.4, 29.4, 24.2. IR neat νmax/ cm-1 : 2962, 2926, 2853, 1630, 1597, 1558, 1503, 1483, 1469, 1137, 1120, 1093, 1079, 
747. HRMS calcd for C25H24N3O [M+H]+ 382.1919, obsd 382.1920. HPLC: [H2O+ 0.1% formic acid / ACN – grd 5-
100] r. t.: 13.13 min, purity: 100%. 
N,9-Dimethyl-N-(2-methyl-6-nitroquinolin-4-yl)-9H-carbazol-3-amine 1g (28%) 
Brown solid. F = 207.6 - 212.4 °C. 1H NMR (300 MHz, CDCl3) δ 8.52 (d, J = 2.4 Hz, 1H), 8.16 (dd, J = 7.4 Hz, J = 2.4 
Hz, 1H), 7.93 (d, J = 6.7 Hz, 1H), 7.91 (d, J = 5.1 Hz, 1H), 7.71 (s, 1H), 7.51 – 7.32 (m, 4H), 7.17 (t, J = 7.4 Hz, 1H), 
6.95 (s, 1H), 3.86 (s, 3H), 3.57 (s, 3H), 2.76 (s, 3H).13C NMR (75 MHz, CDCl3) δ 163.2, 155.6, 152.4, 142.9, 142.4, 
141.7, 138.8, 130.2, 126.3, 123.8, 123.1, 123.0, 122.2, 122.1, 120.5, 120.0, 119.0, 116.2, 110.0 (2), 108.8, 44.5, 29.3, 
26.0. IR film νmax/ cm-1: 2963, 2930, 2854, 2361, 2341, 1735, 1633, 1613, 1522, 1335, 1049. HRMS calcd for 
C24H21N4O2 [M+H]+  397.1665, obsd 397.1662. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 12.54 min, 
purity: 100%. 
9-Ethyl-N-methyl-N-(2-methylquinolin-4-yl)-9H-carbazol-3-amine 1h (44%) 
Brown solid. F = 87.4 - 89.6 °C. 1H NMR (300 MHz, CDCl3) δ 8.55 (d, J = 8.7 Hz, 1H), 8.01 (d, J = 7.8 Hz, 1H), 7.91 
(d, J = 2.2 Hz, 1H), 7.53 – 7.43 (m, 4H), 7.28 – 7.19 (m, 3H), 6.95 (t, J = 6.7 Hz, 1H), 6.86 (s, 1H), 4.40 (q, J = 7.1 Hz, 
2H), 3.78 (s, 3H), 2.99 (s, 3H), 1.46 (t, J = 7.1 Hz, 3H).13C NMR (75 MHz, CDCl3) δ 157.1, 154.2, 140.8, 140.7, 139.7, 
138.5, 131.7, 126.7, 126.3, 125.3, 124.0, 123.0, 122.2, 121.3, 120.7, 119.4, 118.4, 117.2, 110.2, 109.0, 106.0, 46.3, 
37.9, 20.9, 13.9. IR film νmax/ cm-1: 2957, 2924, 2855, 2360, 2340, 1730, 1633, 1594, 1508, 1346, 1042. HRMS calcd 
for C25H24N3 [M+H]+ 366.1970, obsd 366.1965. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 13.39 min, 
purity: 95%. 
N,9-Dimethyl-N-(2-methylquinazolin-4-yl)-9H-carbazol-3-amine 2a (40%) 
Yellow solid. F = 181.5 - 183.6 °C. 1H NMR (300 MHz, CDCl3) δ 7.89 (d, J = 7.7 Hz, 1H), 7.84 (d, J = 2.1 Hz, 1H), 
7.61 (d, J = 8.4 Hz, 1H), 7.39 (q, J = 6.8 Hz, 1H), 7.33 (s, 1H), 7.30 (d, J = 4.2 Hz, 1H), 7.21 – 7.08 (m, 3H), 6.81 (d, J 
= 8.4 Hz, 1H), 6.66 (t, J = 7.7 Hz, 1H), 3.77 (s, 3H), 3.61 (s, 3H), 2.64 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 163.3, 
161.8, 141.7, 140.4 (2), 139.4, 134.0, 131.5, 127.5, 126.4 (2), 124.3, 123.8, 122.4, 120.6, 119.3, 118.1, 114.8, 109.7, 
108.8, 43.4, 29.3, 26.5. IR neat νmax/ cm-1: 3319, 2965, 2924, 2877, 1613, 1602, 1494, 1486, 1393, 1354, 1247. HRMS 
calcd for C23H21N4 [M+H]+ 353.1766, obsd 353.1767. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 14.80 
min, purity: 100%. 
N-(2-Chloroquinazolin-4-yl)-N,9-dimethyl-9H-carbazol-3-amine 2b (62%) 
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Pale yellow solid. F = 231.2 - 232.1 °C. 1H NMR (300 MHz, CDCl3) δ 8.03 (d, J = 9.0 Hz, 1H), 7.98 (d, J = 2.1 Hz, 
1H), 7.71 (d, J = 9.0 Hz, 1H), 7.60 – 7.40 (m, 4H), 7.34 – 7.27 (m, 2H), 6.80 (d, J = 4.1 Hz, 2H), 3.91 (s, 3H), 3.74 (s, 
3H). 13C NMR (75 MHz, CDCl3) δ 162.9, 156.8, 153.2, 141.9, 139.9, 138.9, 132.6, 127.7, 126.8, 126.7, 125.0, 124.3, 
124.1, 122.4, 120.8, 119.6, 118.4, 115.1, 110.1, 109.1, 44.1, 29.5.  IR neat νmax/ cm-1: 3053, 2930, 1632, 1600, 1528, 
1504, 1469, 1393, 927. HRMS calcd for C22H18N4Cl [M+H]+ 373.1220, obsd 373.1227. HPLC [H2O+ 0.1% formic acid 
/ ACN – grd 5-100] r. t.: 21.01 min, purity: 100%. 
N,9-Dimethyl-N-(2-methylpyridin-4-yl)-9H-carbazol-3-amine 3 (37%) 
Pale yellow solid. F = 124.8 - 125.2 °C. 1H NMR (300 MHz, DMSO) δ 8.21 (t, J = 8.4 Hz, 2H), 8.10 (d, J = 2.0 Hz, 
1H), 7.72 (d, J = 8.4 Hz, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.51 (t, J = 8.4 Hz, 1H), 7.38 (dd, J = 8.4 Hz, J = 2.1 Hz, 1H), 
7.23 (t, J = 7.4 Hz, 1H), 6.90 (s, 2H), 3.92 (s, 3H), 3.85 (s, 3H), 2.50 (s, 3H). 13C NMR (75 MHz, DMSO) δ 156.9, 
156.3, 141.2, 139.1, 128.3, 126.4, 122.7, 122.7, 121.6, 120.7 (2), 119.0 (2), 116.5, 110.4 (2), 109.5, 42.1, 29.2, 19.5. IR 
neat νmax/ cm-1: 2959, 2925, 2853, 2360, 1704, 1674, 1573, 1533, 1494, 1430, 1359, 1305, 1205, 1142, 1099. HRMS 
calcd for C20H20N3 [M+H]+ 302.1657, obsd 302.1647. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 10.81 
min, purity: 95%. 
N-(6-Chloro-5-methoxypyridin-2-yl)-N,2-dimethylquinolin-4-amine 6 (29%) 
Brown solid. F = 108.4 - 108.9 °C. 1H NMR (300 MHz, CDCl3) δ 8.05 (d, J = 8.4 Hz, 1H), 7.74 – 7.63 (m, 2H), 7.38 (t, 
J = 8.4 Hz, 1H), 7.16 (s, 1H), 6.96 (d, J = 8.8 Hz, 1H), 6.07 (d, J = 8.8 Hz, 1H), 3.80 (s, 3H), 3.55 (s, 3H), 2.73 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 160.2 (2), 152.5, 151.8, 149.8, 144.6, 137.8, 129.8, 129.3, 125.8, 123.7, 123.5, 118.6, 
109.3, 57.2, 39.2, 25.4. IR neat νmax/ cm-1: 3046, 2959, 2924, 2365, 1748, 1658, 1560, 1480, 1438, 1372, 1235, 1180, 
1014, 891. HRMS calcd for C17H17N3OCl [M+H]+ 314.1060, obsd 314.1052. HPLC [H2O+ 0.1% formic acid / ACN – 
grd 5-100] r. t.: 9.59 min, purity: 98%. 
N-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)-N,2-dimethylquinolin-4-amine 9 (62%) 
Brown solid. F = 137.6 - 143.3 °C. 1H NMR (300 MHz, CDCl3) δ 7.95 (d, J = 8.2 Hz, 1H), 7.65 (d, J = 8.2 Hz, 1H), 
7.53 (t, J = 7.3 Hz, 1H), 7.21 (t, J = 7.3 Hz, 1H), 6.91 (s, 1H), 6.71 (d, J = 8.7 Hz, 1H), 6.48 (d, J = 2.5 Hz, 1H), 6.39 
(dd, J = 8.7 Hz, J = 2.7 Hz, 1H), 4.20 (s, 4H), 3.36 (s, 3H), 2.69 (s, 3H).13C NMR (300 MHz, CDCl3) δ 159.5, 154.0, 
149.5, 144.6, 144.0, 139.3, 129.1, 128.9, 124.8, 124.6, 122.4, 117.7, 114.5, 113.0, 110.1, 64.6, 64.3, 42.8, 25.5. IR neat 
νmax/ cm-1: 2970, 2924, 2873, 2361, 1734, 1615, 1562, 1433, 1385, 1277, 1122, 1048, 910. HRMS calcd for C19H19N2O2 
[M+H]+ 307.1447, obsd 307.1443. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 9.77 min, purity: 100%. 
N-(2-Methoxy-5-(1-(2-methylquinolin-4-yl)vinyl)phenyl)-N,2-dimethylquinolin-4-amine 11 (12%) 
Brown solid. F = 167.2 - 168.4 °C. 1H NMR (300 MHz, CDCl3) δ 8.76 (d, J = 8.3 Hz, 1H), 8.02 (d, J = 8.3 Hz, 1H), 
7.79 (d, J = 8.3 Hz, 1H), 7.62 (t, J = 7.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H),  7.42 – 7.31 (m, 3H), 7.26 (s, 1H), 7.00 (d, J 
= 6.7 Hz, 2H), 6.86 (d, J = 8.8 Hz, 1H), 5.93 (s, 1H), 5.64 (s, 1H), 5.29 (s, 1H), 3.77 (s, 3H), 3.62 (s, 3H), 2.76 (s, 3H), 
2.20 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 158.8, 155.4, 152.3, 149.0, 148.1, 147.6, 145.9, 140.6, 138.6, 133.1, 131.5, 
129.1, 128.8, 126.3, 126.2, 125.5, 125.4, 123.8, 123.2, 122.5, 122.4, 122.0, 115.1, 114.9, 111.8, 102.3, 56.0, 34.4, 25.4, 
22.2. IR neat νmax/ cm-1: 3005, 2961, 2924, 2853, 2186, 1702, 1621, 1591, 1469, 1178, 1144. HRMS calcd for 
C30H28N3O [M+H]+ 446.2232, obsd 446.2242. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 8.62 min, 
purity: 99%. 
N-(Dibenzo[b,d]furan-2-yl)-N,2-dimethylquinolin-4-amine 12 (86%) 
Brown solid. F = 252.0 - 256.0 °C. 1H NMR (300 MHz, CDCl3) δ 8.00 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 7.3 Hz, 1H), 
7.63 (d, J = 8.4 Hz, 1H), 7.56 – 7.46 (m, 3H), 7.39 (d, J = 8.7 Hz, 2H), 7.22 (d, J = 7.3 Hz, 1H), 7.14 (t, J = 8.4 Hz, 
1H), 7.04 (dd, J = 8.7 Hz, J = 2.4 Hz, 1H), 6.98 (s, 1H), 3.48 (s, 3H), 2.73 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.5, 
156.8, 154.1, 152.2, 149.7, 146.3, 129.0, 129.0, 127.3, 125.0, 124.8, 124.5, 124.0, 122.6, 122.1, 121.7, 120.7, 113.0, 
112.8, 112.3, 111.7, 43.3, 25.6. IR neat νmax/ cm-1: 3051, 3008, 2960, 2923, 2851, 2186, 1733, 1615, 1589, 1475, 1196, 
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1171, 770, 757, 745. HRMS calcd for C23H19N2O [M+H]+ 339.1497, obsd 339.1496. HPLC [H2O+ 0.1% formic acid / 
ACN – grd 5-100] r. t.: 12.61 min, purity: 96%. 
N-Methyl-N-(2-methylquinolin-4-yl)-9H-carbazol-3-amine 1i (12%) 
In a dry sealed tube was added 1e (85 mg, 0.2 mmol) in trifluoroacetic acid (3 mL) with triflic acid (4 drops). The 
mixture was stirred at 85 °C for 4 h. Dichloromethane was added to the cooled mixture and the organic layer was 
washed with water, dried on Na2SO4 and filtered. The filtrate was concentrated under vacuo and purified by silica gel 
column chromatography with dichloromethane/methanol [95/5] to give 1i (8 mg, 12%).  
Yellow solid. F = 147.5 - 149.2 °C. 1H NMR (400 MHz, MeOD) δ 7.96 – 7.93 (m, 2H), 7.77 (d, J = 8.3 Hz, 1H), 7.57 
(t, J = 7.4 Hz, 1H), 7.53 (d, J = 8.6 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.28 – 7.20 (m, 2H), 7.12 
(t, J = 7.4 Hz, 1H), 7.04 (s, 1H), 6.95 (t, J = 7.4 Hz, 1H), 3.73 (s, 3H), 2.76 (s, 3H). 13C NMR (101 MHz, MeOD) δ 
158.9, 155.6, 142.4, 142.2, 141.2, 140.2, 133.1, 129.1, 128.1, 127.5, 126.0, 125.5, 124.2, 123.8, 121.7, 121.3, 120.2, 
118.2, 113.5, 112.2, 106.8, 46.4, 20.9. IR neat νmax/ cm-1: 3471, 3065, 3026, 2413, 2360, 1732, 1668, 1614, 1579, 1521, 
1488, 1261, 1161, 1016. HRMS calcd for C23H20N3 [M+H]+ 338.1657, obsd 338.1654. HPLC [H2O+ 0.1% formic acid / 
ACN – grd 5-100] r. t.: 11.79 min, purity: 97%. 
1-(9-Methyl-6-(methyl(2-methylquinolin-4-yl)amino)-9H-carbazol-3-yl)ethanol 1j (80%) 
In a two necked flask was added 1a (40 mg, 0.11 mmol) and AlCl3 (15 mg, 0.11 mmol, 1 equiv.) in dichloromethane (3 
mL).The mixture was refluxed and acetyl chloride (8 µL, 0.11 mmol, 1 equiv.) was added dropwise. The mixture was 
stirred at reflux for 4 h. The solvent was distilled off and a mixture of dichloromethane/water [1/1] (1mL) was added to 
the crude mixture. Sodium borohydride (7 mg, 0.11 mmol, 1 equiv.) was added portion wise and the mixture was stirred 
at room temperature for 4 h. Water was added slowly and the aqueous layer was extracted with dichloromethane. 
Organic layers were dried on Na2SO4 and filtered. The crude mixture was concentrated under vacuo and purified by 
silica gel column chromatography with dichloromethane/methanol [95/5] to give 1j (35 mg, 80%). 
Yellow solid. F = 152.4 - 156.8 °C. 1H NMR (300 MHz, MeOD) δ 8.05 (s, 2H), 7.82 (d, J = 8.3 Hz, 1H), 7.69 – 7.51 
(m, 5H), 7.41 (dd, J = 8.8 Hz, J = 1.4 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.16 (s, 1H), 7.05 (t, J = 8.3 Hz, 1H), 5.02 (q, J 
= 6.6 Hz, 1H), 3.95 (s, 3H), 3.81 (s, 3H), 2.82 (s, 3H), 1.55 (d, J = 6.6 Hz, 3H).13C NMR (75 MHz, MeOD) δ 158.5, 
157.2, 146.8, 143.2, 142.5, 140.5, 138.4, 131.1, 127.3, 125.6, 125.5 125.3, 124.9, 124.0, 123.3, 121.2, 118.3, 117.2, 
111.0, 109.7, 71.2, 49.0, 45.5, 29.5 (2), 25.9. IR neat νmax/ cm-1: 3407, 2924, 2853, 2341, 1635, 1596, 1509, 1490, 1424, 
1348, 1179, 1072, 1007. HRMS calcd for C26H26N3O [M+H]+ 396.2076, obsd 396.2075. HPLC [H2O+ 0.1% formic 
acid / ACN – grd 5-100] r. t.: 11.20 min, purity: 98%. 
N,9-Dimethyl-N-(2-methylquinolin-4-yl)-6-nitro-9H-carbazol-3-amine 1k 
To a solution of 1a (600 mg, 1.71 mmol) in dichloromethane (30 mL) was added dropwise HNO3 (69%, 111 µL, 1.71 
mmol, 1 equiv.) at 0 °C and under inert atmosphere. After complete addition of HNO3 the reaction was stirred at room 
temperature for 3 h. The crude mixture was concentred and purified by chromatography on silica gel 
(dichloromethane/methanol) [95/5], and 9k was obtained (487 mg, 72%). 
Orange cristal. F = 182.4 – 183.4 °C. 1H NMR (300 MHz, CDCl3) δ 7.92 (t, J = 8.0 Hz, 2H), 7.62 (d, J = 8.1 Hz, 1H), 
7.58 (d, J = 7.3 Hz, 1H), 7.49 – 7.43 (m, 2H), 7.32 (t, J = 8.6 Hz, 2H), 7.03 (m, 2H), 6.93 (s, 1H), 3.85 (s, 3H), 3.46 (s, 
3H), 2.74 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.1, 153.2, 149.7, 142.1, 140.9, 139.7, 134.5, 129.1, 128.9, 127.9, 
124.6, 124.5, 124.3, 122.0, 121.0, 120.5, 118.6, 115.0, 111.8, 109.6, 109.3, 44.2, 29.5, 25.9.  IR film νmax/ cm-1 : 
2957, 2832, 2341, 1845, 1734, 1684, 1559, 1525, 1475, 1157, 682. HRMS calcd for C24H21N4O2 [M+H]+ 396.1665, 
obsd 397.1668. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 12.56 min,  purity : 100%. 
N-3,9-Dimethyl-N3-(2-methylquinolin-4-yl)-9H-carbazole-3,6-diamine 1l 
In a two necked flask was added 1k (100 mg, 0.25 mmol) and Pd/C (10%, 6 mg, 0.02 equiv.) in ethanol (3 mL). 
Hydrazine (0.5 mL) was added slowly and the reaction mixture was stirred at reflux for 6 h. The crude mixture was 
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cooled and filtered on a celite pad. The crude mixture was concentrated and purified by chromatography on silica gel 
dichloromethane/ethanol [90/10] and 1l was obtained (143 mg, 87%). 
Yellow solid. F = 137.8 - 138.3 °C. 1H NMR (300 MHz, MeOD) δ 8.78 (d, J = 8.4 Hz, 1H), 8.04 (t, J = 7.6 Hz, 1H), 
7.93 (d, J = 8.2 Hz, 1H), 7.85 (t, J = 7.6 Hz, 1H), 7.59 (d, J = 8.8 Hz, 1H), 7.55 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 8.2 Hz, 
1H), 7.35 (t, J = 7.5 Hz, 1H), 7.16 (d, J = 8.8 Hz, 1H), 6.85 (t, J = 7.6 Hz, 1H), 6.09 (s, 1H), 3.87 (s, 3H), 2.90 (s, 3H), 
2.40 (s, 3H). 13C NMR (75 MHz, MeOD) δ 157.8, 155.9, 143.0, 141.3, 140.6, 136.4, 134.8, 128.0, 127.0, 124.3, 122.5, 
121.5, 121.2, 121.0, 119.4, 117.9, 115.7, 112.7, 111.2, 109.8, 101.4, 31.8, 29.4, 20.4. IR film νmax/ cm-1: 2924, 2853, 
2341, 2327, 2273, 1845, 1734, 1635, 1603, 1558, 1521, 1474, 1438, 1365, 1338, 1090. HRMS calcd for C24H23N4 
[M+H]+ 367.1923, obsd 367.1931. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 9.64 min, purity: 93%. 
2-Methyl-4-(methyl(9-methyl-9H-carbazol-3-yl)amino)quinolin-8-ol 1m 
To a solution of 1f (20 mg, 0.05 mmol) in dry dichloromethane (1 mL) was added dropwise BBr3 (10 µL, 0.05 mmol, 2 
equiv.) at -50 °C and under argon atmosphere. After complete addition, the reaction mixture was stirred at room 
temperature for 2 h. The pH mixture was adjust to pH = 8 with NaHCO3(aq.), the organic layer was separated and the 
aqueous layer was extracted with dichloromethane. The organic layers were dried on Na2SO4 and filtered. The filtrate 
was concentrated under vacuo and purified by silica gel column chromatography with dichloromethane/methanol [95/5] 
to give 1m (17 mg, 87%). 
Brown solid. F = 222.4 - 223.4 °C. 1H NMR (300 MHz, CDCl3) δ 7.97 (d, J = 7.8 Hz, 1H), 7.80 (d, J = 2.1 Hz, 1H), 
7.47 (t, J = 8.7 Hz, 1H), 7.39 (d, J = 8.2 Hz, 1H), 7.29 (d, J = 8.7 Hz, 1H), 7.22 - 7.15 (m, 2H), 6.97 – 6.84 (m, 4H), 
3.84 (s, 3H), 3.55 (s, 3H), 2.70 (s, 3H), OH not seen. 13C NMR (75 MHz, CDCl3) δ 157.1, 154.5, 152.0, 143.2, 141.7, 
139.6, 138.3, 126.2, 124.6, 123.6 (2), 122.7, 121.5, 120.6, 119.0, 115.9, 115.4, 110.7, 109.4, 108.9, 108.8, 44.4, 29.4, 
25.3. IR neat νmax/ cm-1 : 3051, 2878, 2360, 1564, 1511, 1484, 1471, 1424, 1357, 1293, 1243, 1083. HRMS calcd for 
C24H22N3O [M+H]+ 368.1763, obsd 368.1772. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 12.40 min, 
purity: 100%. 
N-4,2-Dimethyl-N4-(9-methyl-9H-carbazol-3-yl)quinoline-4,6-diamine 1n 
In a two necked flask was added 1g (180 mg, 0.45 mmol) in a mixture of ethanol/water [8/2]. The resulting suspension 
was stirred at 90 °C until complete dissolution. Iron (254 mg, 4.5 mmol, 10 equiv.) and HCl (12 N, 3 drops) were added 
and the mixture was stirred at 90 °C for 4 h. The mixture was cooled to room temperature and filtered on paper. The 
filtrate was concentrated under vacuo and purified by silica gel column chromatography with 
dichloromethane/methanol [95/5] to give 1n (143 mg, 87%). 
Pale yellow solid. F = 192.6 - 196.5 °C. 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 7.7 Hz, 2H), 7.81 (d, J = 2.1 Hz, 
1H), 7.52 (t, J = 7.5 Hz, 1H), 7.42 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.24 (t, J = 7.5 Hz, 1H), 7.15 (dd, J = 
7.7 Hz, J = 2.1 Hz, 1H), 6.98 (d, J = 11.1 Hz, 1H), 6.83 (s, 1H), 6.57 (s, 1H), 4.78 (s, 2H), 3.87 (s, 3H), 3.60 (s, 3H), 
2.79 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.8, 153.0, 143.3, 142.9, 141.7, 137.6, 134.4, 130.2, 126.0, 123.6, 123.5, 
122.6, 121.2, 120.8, 120.6, 118.8, 113.2, 112.9, 109.2, 108.7, 106.4, 43.7, 29.3, 25.3. IR neat νmax/ cm-1: 2928, 2360, 
2341, 1744, 1623, 1470, 1426, 1248, 1122. HRMS calcd for C24H23N4 [M+H]+ 367.1923, obsd 367.1916. HPLC [H2O+ 
0.1% formic acid / ACN – grd 5-100] r. t.: 12.04 min, purity: 97%.  
N,N,9-Trimethyl-N-(quinolin-4-yl)-9H-carbazol-3-aminium 1o 
In a sealed tube were added successively 4-bromoquinoline (156 mg, 0.75 mmol, 1 equiv.) and 9-methyl-9H-carbazol-
3-amine (146 mg, 0.75 mmol, 1 equiv.) in dioxane (2 mL). One drop of HCl (12 N) was added and the mixture was 
stirred at 100 °C for 12 h. EtOAc was added to the cooled mixture which was neutralized with NaOHaq. (5 N). After 
extraction, organic layer were dried (Na2SO4) and concentrated under vacuo. The crude was added to a solution of 
Cs2CO3 (585 mg, 1.8 mmol, 2.4 equiv.) in DMF (5 mL) at 0 °C. CH3I (112 µL, 1.8 mmol, 2.4 equiv.) was added 
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dropwise at 0 °C and the mixture was stirred at room temperature for 12 h. The crude mixture was concentrated and 
purified by silica gel column chromatography with dichloromethane/methanol [90/10] to give 1o (64 mg, 18%). 
Red solid. F = 294.7 - 296.2 °C. 1H NMR (300 MHz, DMSO) δ 8.88 (d, J = 7.3 Hz, 1H), 8.24 (d, J = 1.9 Hz, 1H), 8.10 
(d, J = 8.4 Hz, 2H), 7.84 (t, J = 7.7 Hz, 1H), 7.72 (d, J = 8.7 Hz, 1H), 7.64 (d, J = 8.3 Hz, 1H), 7.51 (t, J = 7.7 Hz, 1H), 
7.45 (d, J = 8.8 Hz, 2H), 7.34 (d, J = 7.3 Hz, 1H), 7.29 – 7.17 (m, 2H), 4.26 (s, 3H), 3.92 (s, 3H), 3.80 (s, 3H). 13C 
NMR (75 MHz, DMSO) δ 157.5, 146.9, 141.4, 139.7, 139.6, 139.3, 133.1, 127.2, 126.6, 125.6, 123.3, 122.9, 121.6, 
120.7, 119.3, 119.2, 118.8, 117.4, 110.9, 109.7, 105.4, 46.1, 42.6, 29.3. IR neat νmax/ cm-1: 3120, 3035, 30006, 2924, 
1596, 1542, 1495, 1482, 1457, 1431, 1347, 1320, 1238. HRMS calcd for C24H23N4 [M+H]+ 352.1808, obsd 352.1869. 
HPLC [H2O + 0.1% formic acid / ACN – grd 5-100] r. t.: 14.15 min, purity: 98%. 
N-(2-Chloroquinolin-4-yl)-N,9-dimethyl-9H-carbazol-3-amine 1p 
In a dry sealed tube and under an argon atmosphere were added successively 2-hydroxyquinolin-4-yl 
trifluoromethanesulfonate (26 mg, 0.14 mmol, 1 equiv.), 9-methyl-9H-carbazol-3-amine (40 mg, 0.21 mmol, 1.5 
equiv.), Pd2dba3 (8 mg, 0.01 mmol, 6%), ± BINAP (11 mg, 0.02 mmol, 12%), Cs2CO3 (112 mg, 0.35 mmol, 2.5 equiv.) 
in dry dioxane (1.7 mL). The mixture was stirred at 130 °C under Microwave Irradiation for 1 h 30. The resulting 
suspension was cooled to room temperature, filtered through a pad of celite eluting with dichloromethane/methanol 
[8/2]. The filtrate was concentrated under vacuo and the crude mixture was added to a dry flask with POCl3 (3 mL) and 
NEt3 (0.5 mL) was added dropwise. The mixture was stirred at 90 °C for 4 h. The crude mixture was concentrated and 
ethyl acetate was added. The organic layer was washed with a NaHCO3 (sat.) solution, dried on Na2SO4 and filtered. The 
filtrate was concentrated and the crude mixture was added to a solution of Cs2CO3 (70 mg, 0.35 mmol, 1.5 equiv.) in 
DMF (5mL) at 0 °C. CH3I (14 µL, 0.35 mmol, 1.5 equiv.) was added dropwise at 0 °C and the mixture was stirred at 
room temperature for 12 h. The crude mixture was concentrated and purified by silica gel column chromatography with 
cyclohexane/ethyl acetate [90/10] to give 1p (4 mg, 8%). 
Yellow solid. F = 137.5 - 139.2 °C. 1H NMR (300 MHz, CDCl3) δ 7.98 (d, J = 7.8 Hz, 1H), 7.89 (dd, J = 8.8 Hz, J = 1.4 
Hz, 1H), 7.81 (d, J = 2.2 Hz, 1H), 7.51 – 7.43 (m, 3H), 7.40 (d, J = 8.2 Hz, 1H), 7.32 (d, J = 8.8 Hz, 1H), 7.24 – 7.16 
(m, 2H), 7.02 – 6.96 (m, 2H), 3.85 (s, 3H), 3.55 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 156.1, 151.7, 149.4, 142.8, 
141.8, 138.6, 129.6, 129.0, 126.4, 125.9, 124.9, 123.8, 122.9, 122.4, 121.7, 120.7, 119.2, 116.2, 109.6, 109.1, 108.9, 
44.9, 29.4. IR neat νmax/ cm-1: 2937, 2351, 2312, 1795, 1656, 1445, 1427, 1289, 1101. HRMS calcd for C23H19ClN3 
[M+H]+ 372.1268, obsd 372.1212. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 21.47 min, purity: 98%. 
4.3. General procedure for the synthesis of compounds 4a and 4b 
In a dry sealed tube and under argon atmosphere were added successively ArCl, aniline, Pd2dba3 (10%), Xphos (20%), 
NaOtBu (3 equiv.) in dry toluene (2 mL). The mixture was stirred at 100 °C for 12 h. The resulting suspension was 
cooled to room temperature, filtered through a pad of celite eluting with ethyl acetate and inorganic salts were removed. 
The filtrate was concentrated and the crude mixture was added to a solution of Cs2CO3 (1.2 equiv.) in DMF (5mL) at 0 
°C. CH3I (1.2 equiv.) was added dropwise at 0 °C and the mixture was stirred at room temperature for 12 h. The crude 
mixture was concentrated and purified by silica gel column chromatography.  
N,2-Dimethyl-N-(1-methyl-1H-indol-5-yl)quinolin-4-amine 4a (14%) 
Beige solid, F = 130.5 - 132.2 °C. 1H NMR (300 MHz, CDCl3) δ 7.94 (d, J = 8.3 Hz, 1H), 7.61 (d, J = 8.4 Hz, 1H), 7.48 
(t, J = 7.6 Hz, 1H), 7.29 (d, J = 2.0 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 7.10 – 7.02 (m, 2H), 6.96 (dd, J = 8.7, J = 2.0 Hz, 
1H), 6.91 (s, 1H), 6.38 (d, J = 3.0 Hz, 1H), 3.78 (s, 3H), 3.50 (s, 3H), 2.74 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.4, 
154.6, 149.7, 144.0, 134.0, 129.9, 129.2, 128.9, 128.7, 125.4, 124.0, 121.9, 118.7, 115.0, 110.8, 110.2, 101.0, 44.2, 
33.1, 25.8. IR neat νmax/ cm-1 : 1585, 1509, 1486, 1393, 1366, 1338, 1294, 1263, 1174, 1151, 1107, 1095, 1078, 1031. 
HRMS calcd for C20H20N3 [M+H]+ 302.1657, obsd 302.1667. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 
21.72 min, purity: 100%. 
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N-Methyl-N-(1-methyl-1H-indol-5-yl)-2-(trifluoromethyl)quinolin-4-amine 4b (62%) 
Pale yellow solid. F = 108.5 - 109.5 °C. 1H NMR (300 MHz, CDCl3) δ 8.02 (d, J = 8.5 Hz, 1H), 7.54 – 7.43 (m, 2H), 
7.27 (d, J = 2.0 Hz, 1H), 7.19 (d, J = 7.6 Hz, 2H), 7.09 – 6.99 (m, 2H), 6.91 (dd, J = 8.5 Hz, J = 2.0 Hz, 1H), 6.33 (d, J 
= 3.1 Hz, 1H), 3.73 (s, 3H), 3.49 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 155.7, 149.0, 148.4 (q, J = 33 Hz), 143.2, 134.4, 
130.3, 130.1, 129.4, 129.1, 125.9, 125.7, 122.9, 122.0 (q, J = 273 Hz), 119.0, 116.3, 110.5, 103.8, 101.1, 44.6, 33.0. 19F 
NMR (188 MHz, CDCl3) δ - 67.84. IR neat νmax/ cm-1: 2963, 2926, 2853, 1598, 1569, 1513, 1488, 1365, 1189, 1154, 
1128, 1111, 1093. HRMS calcd for C20H17F3N3 [M+H]+ 356.1375, obsd 356.1371. HPLC [H2O+ 0.1% formic acid / 
ACN – grd 5-100]  r. t.: 20.22 min, purity: 99%. 
4-(5-Methoxy-1H-indol-1-yl)-2-methylquinoline 5 (95%) 
In a dry sealed tube and under argon atmosphere were added successively 4-chloro-2-methylquinoline (178 mg, 1 
mmol, 1 equiv.), 5-methoxy-1H-indole (177 mg, 1.2 mmol, 1.2 equiv.), Pd(OAc)2 (23 mg, 0.1 mmol, 10%), Xantphos 
(58 mg, 0.1mmol, 10%), Cs2CO3 (586 mg, 1.8 mmol, 1.8 equiv.) in dry dioxane (3 mL). The mixture was stirred at 130 
°C for 24 h. The resulting suspension was cooled to room temperature, filtered through a pad of celite eluting with ethyl 
acetate and inorganic salts were removed. The filtrate was concentrated and purified by silica gel column 
chromatography with cyclohexane/ethyl acetate [80/20] to give 5 (274 mg, 95%). 
Brown solid. F = 112.1 - 113.5 °C. 1H NMR (300 MHz, CDCl3) δ 8.14 (d, J = 8.4 Hz, 1H), 7.79 – 7.68 (m, 2H), 7.44 (t, 
J = 8.4 Hz, 1H), 7.35 (d, J = 3.5 Hz, 2H), 7.19 (d, J = 2.2 Hz, 1H), 7.09 (d, J = 8.9 Hz, 1H), 6.85 (dd, J = 8.9 Hz, J = 2.2 
Hz, 1H), 6.73 (d, J = 3.5 Hz, 1H), 3.89 (s, 3H), 2.81 (s, 3H).13C NMR (300 MHz, CDCl3) δ 159.6, 155.1, 149.8, 144.6, 
132.4, 130.3, 129.8, 129.6, 129.3, 126.4, 123.6, 123.1, 118.9, 112.9, 111.8, 104.5, 103.0, 56.0, 25.5. IR neat νmax/ cm-1: 
3094, 2930, 1616, 1510, 1241, 1205, 1053, 759, 724. HRMS calcd for C19H17N2O [M+H]+ 289.1341, obsd 289.1339. 
HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 12.21 min, purity: 100%. 
3-Methoxy-6-(methyl(2-methylquinolin-4-yl)amino)pyridin-2-ol 7 (54%) 
In a dry sealed tube and under argon atmosphere were added successively 6 (80 mg, 0.26 mmol, 1 equiv.), KOH (29 
mg, 0.52 mmol, 2 equiv.), Pd2dba3 (27 mg, 0.03 mmol, 10%), tBuXphos (5 mg, 0.02 mmol, 5%), in a mixture of 
dioxane/water [1/1] (2 mL). The mixture was stirred at 90 °C for 12 h. The resulting suspension was cooled to room 
temperature and water was added. The aqueous layer was extracted with ethyl acetate. The organic layers were dried on 
Na2SO4 and filtered on paper. The filtrate was concentrated and purified by silica gel column chromatography with 
dichloromethane/methanol [90/10] to give 7 (42 mg, 54%). 
Brown solid. F = 228.5 - 229.2 °C 1H NMR (300 MHz, DMSO) δ 11.20 (s, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.60 (t, J = 
7.6 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.34 (t, J = 7.6 Hz, 1H), 7.17 (s, 1H), 6.87 (d, J = 8.1 Hz, 1H), 5.61 (d, J = 8.1 
Hz, 1H), 3.64 (s, 3H), 3.37 (s, 3H), 2.62 (s, 3H). 13C NMR (75 MHz, DMSO) δ 159.4 (2), 155.4, 151.7, 148.8, 129.05, 
128.74, 124.93, 123.58, 122.1 (2), 119.26, 114.24, 99.09, 55.90, 40.38, 24.94. IR neat νmax/ cm-1: 3393, 2907, 2884, 
1651, 1616, 1589, 1412, 1365, 1248, 1231, 1024, 1003, 988, 775. HRMS calcd for C17H18N3O2 [M+H]+ 296.1399, obsd 
296.1393. HPLC [H2O+ 0.1% formic acid / ACN – grd 5-100] r. t.: 6.11 min, purity: 91%. 
5-Methoxy-N2-methyl-N2-(2-methylquinolin-4-yl)pyridine-2,6-diamine 8 (62%) 
In a dry sealed tube and under argon atmosphere were added successively 6 (179 mg, 0.5 mmol, 1 equiv.), Pd2dba3 (26 
mg, 5%), tBuBretphos (24 mg, 0.05 mmol, 10%), NaOtBu (67 mg, 0.75 mmol, 1.5 equiv.) in dry dioxane (3 mL). The 
reaction mixture was stirred at room temperature for 5 min. Then, NH3 solution in dioxane (3 mL, 0.5 M, 1.5 mmol, 3 
equiv.) was added and the mixture was stirred at 100 °C for 6 h. The resulting suspension was cooled to room 
temperature, filtered through a pad of celite eluting with dichloromethane/methanol [80/20] and inorganic salts were 
removed. The filtrate was concentrated and purified by silica gel column chromatography with 
dichloromethane/methanol [8/2] to give 8 (91 mg, 62%). 
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Yellow solid. F = 112.8 - 114.7 °C. 1H NMR (300 MHz, CDCl3) δ 7.99 (d, J = 8.3 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 
7.58 (td, J = 7.6 Hz, J = 1.2 Hz, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.06 (s, 1H), 6.72 (d, J = 8.3 Hz, 1H), 5.66 (d, J = 8.3 Hz, 
1H), 4.57 (s, 2H), 3.75 (s, 3H), 3.50 (s, 3H), 2.72 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.9, 153.1, 152.2, 149.7, 
148.5, 136.7, 129.3, 129.1, 124.9, 124.6, 123.5, 118.9, 116.0, 101.1, 56.1, 39.7, 25.6. IR neat νmax/ cm-1 : 3488, 3433, 
3158, 2958, 1631, 1460, 1420, 1215. HRMS calcd for C17H19N4O [M+H]+ 295.1559, obsd 295.1556. HPLC [H2O+ 
0.1% formic acid / ACN – grd 5-100 r. t.: 7.75 min, purity: 98%. 
2-Chloro-N-methyl-N-(1-methyl-1H-indol-5-yl)quinazolin-4-amine 10 (10%) 
In a dry sealed tube and under argon gas was added 2,4-dichloroquinazoline (139 mg, 0.70 mmol, 1 equiv.), 1-methyl-
1H-indol-5-amine (83 mg, 0.84 mmol, 1.2 equiv.) and tBuOK (102 mg, 0.91 mmol, 1.3 equiv.) in THF/water [2/1] (10 
mL). The mixture was stirred at room temperature for 48 h. Water (40 mL) was added and the crude mixture was 
extracted with ethyl acetate (3X40 mL). The organic layer was dried on on Na2SO4 and filtered. The crude mixture was 
added to a solution of NaH (84 mg, 3.5 mmol, 5 equiv.) in DMF (5mL) at 0 °C. CH3I (218 µL, 2.5 mmol, 5 equiv.) was 
added dropwise at 0°C and the mixture was stirred at room temperature for 12 h. The crude mixture was concentrated 
and purified by silica gel column chromatography with dichloromethane/methanol [90/10] to give 10 (16 mg, 10%). 
White solid, F = 173.2 - 176.6 °C. 1H NMR (300 MHz, CDCl3) δ 8.11 (d, J = 7.7 Hz, 1H), 8.05 (d, J = 1.9 Hz, 1H), 
8.02 (d, J = 9.3 Hz, 1H), 7.88 (d, J = 8.1 Hz, 1H), 7.65 (t, J = 7.6 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.48 (t, J = 9.3 Hz, 
2H), 7.41 (dd, J = 8.6 Hz, J = 2.0 Hz, 1H), 7.32 (m, 2H), 6.76 (s, 1H), 3.91 (s, 3H), 3.75 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 157.7, 148.8, 142.1, 141.7, 139.7, 137.5, 130.5, 126.9, 126.4, 125.5, 124.1, 122.8, 122.5, 121.4, 120.6, 119.5, 
119.4, 111.5, 110.0, 108.9, 39.6, 29.3. IR neat νmax/ cm-1 : 1565, 1503, 1488, 1445, 1423, 1399, 1365, 1334, 1301, 1281, 
1268, 1243, 1208, 1168, 1093, 1013. HRMS calcd for C23H19N3Cl [M + H]+ 323.1063, obsd 323.1062. HPLC [H2O+ 
0.1% formic acid / ACN – grd 5-100] r. t.: 18.69 min, purity: 100%. 
5. Biolology 
5.1. Cell Culture and Proliferation Assay 
Cancer cell lines were obtained from the American type Culture Collection (ATCC, Rockville, MD) or from the 
German collection of microorganism and cell culture from the Leibniz Institute (DSMZ, Braunschweig- Germany) or 
from the European collection of cell culture (ECACC, England). Cancer cell lines were cultured according to the 
supplier’s instructions. Primary Human Umbilical Vein Endothelial Cells (HUVEC) isolated from the vein of the 
umbilical cord were obtained from Promocell (Germany). Human HCT-116 colorectal carcinoma were grown in Gibco 
McCoy’s 5A supplemented with 10% fetal calf serum (FCS) and 1% glutamine. A2780, A2780R, K662 and K562R 
cells were grown in Gibco medium RPMI 1640 supplemented with 10% fetal calf serum (FCS) and 1% glutamine. 
JIMT-T1 and Mia-Paca2 cells were grown in Gibco medium DMEM supplemented with 10% fetal calf serum (FCS) 
and 1% glutamine. HUVECs were grown in Endothelial Cell Growth Medium 2 which is low-serum (2% V/V) media 
optimized for the cultivation of endothelial cells from large blood vessels. All cell lines were maintained at 37°C in a 
humidified atmosphere containing 5% CO2. Cell growth inhibition was determined by an MTS assay according to the 
manufacturer’s instructions (Promega, Madison, WI, USA). Briefly, the cells were seeded in 96-well plates (2.5 × 103 
cells/well) containing 100 μL of growth medium. After 24 h of culture, the cells were treated with the tested compounds 
at 8 different final concentrations. After 72 h of incubation, 20 μL of CellTiter 96® AQueous One Solution Reagent was 
added for 2h before recording absorbance at 490nm with a spectrophotometric plate reader. The dose-response curves 
were plotted with Graph Prism software and the IC50 values were calculated using the Graph Prism software from 
polynomial curves (four or five-parameter logistic equations).  
5.2. Cord disruption assays 
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HUVECs (2 x 104 cells per well) were plated in 96-well plates on a thick layer of Matrigel (Becton Dickinson; 10 
mg.mL-1, 60 L per well) and allowed to align for 24 h. Compound 1a (10 nM) or DMSO (vehicle) were added to the 
formed cords and left for 5 h. Images were taken 2 h, 3 h and 5 h after the addition of compounds. 
5.3. Tubulin Binding Assay 
Sheep brain tubulin was purified according to the method of Shelanski [30] by two cycles of assembly-disassembly and 
then dissolved in the assembly buffer containing 0.1 M MES, 0.5 mM MgCl2, 1 mM EGTA, and 1 mM GTP, pH 6.6 
(the concentration of tubulin was about 2-3 mg/mL). Tubulin assembly was monitored by fluorescence according to 
reported procedure [31] using DAPI as fluorescent molecule. Assays were realized on 96-well plates prepared with 
Biomek NKMC and Biomek 3000 from Beckman Coulter and read at 37 °C on Wallac Victor fluorimeter from Perkin 
Elmer. The IC50 value of each compound was determined as the concentration which decreased the maximum assembly 
rate of tubulin by 50% compared to the rate in the absence of compound. The IC50 values for all compounds were 
compared to the IC50 of isoCA-4 and measured the same day under the same conditions. 
5.4. Cell Cycle Analysis 
Exponentially growing cancer HCT116 cells were incubated with 1a at different concentrations (1, 5 and 10 nM) or in 
DMSO alone for 24 h. Cell-cycle profiles were determined by flow cytometry on a FC500 flow cytometer (Beckman-
Coulter, France) as described previously. [32] 
5.5 Apoptosis 
Apoptosis was measured by the Apo-one homogeneous caspase-3/7 assay (Promega Co, WI) according to the 
manufacturer’s recommendations. Briefly, HCT116 cells were subcultured on a 96-well plate with 5 × 104 cells/well in 
100 μL medium. After 24 h of incubation, the medium in the 96-well plate was discarded and replaced with medium 
containing 1a at different concentrations (0.5, 1, 5 and 10 nM) or 0.1% DMSO (as negative control). The HCT116 cells 
were incubated for 24 h, each well then received 100 μL of a mixture of caspase substrate and Apo-one caspase 3/7 
buffer. After 1 h of incubation, the fluorescence of sample was measured using a Victor microtiter plate fluorimeter 
(Perkin-Elmer, USA) at 527 nm. 
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